SCHEMBL883746

SCHEMBL883746

CCCCCC1CCC(C2CCC(C(=O)OC(CC)C3CCCCC3)CC2)CC1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTSK P43235 1/20 0.42
CCR2 P41597 1/20 0.41
TP53 P04637 1/20 0.39
PKM P14618 1/20 0.39
HTT P42858 2/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
CYP1A2 P05177 2/20 0.38
CYP2D6 P10635 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38
POLB P06746 1/20 0.34
HPGD P15428 1/20 0.34
TSHR P16473 1/20 0.34
MAPT P10636 2/20 0.33
LMNA P02545 1/20 0.33
MAPK1 P28482 1/20 0.33
GAA P10253 1/20 0.33
EPHX1 P07099 1/20 0.33
NAAA Q02083 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17147338 0.91 CTSK (0.35) CTSKCCR2CYP1A2
SCHEMBL13767051 0.90 CTSK (0.40) CTSKCCR2TP53PKMHTT
SCHEMBL13095730 0.88 TP53 (0.43) CTSKCCR2TP53PKMHTT
SCHEMBL14451346 0.86 SHBG (0.33) HTTPOLBEPHX1
SCHEMBL13239386 0.82 TSHR (0.37) CTSKTSHREPHX1NAAA
SCHEMBL12152925 0.82 EPHX1 (0.35) CTSKTSHRMAPK1EPHX1
SCHEMBL9607899 0.82 SHBG (0.35) CTSKEPHX1
SCHEMBL13239393 0.80 PKM (0.37) CTSKCCR2TP53PKMHTT
SCHEMBL15128248 0.80 CTSK (0.39) CTSKCCR2TP53PKMHTT
SCHEMBL13701727 0.79 MEN1 (0.38) CTSKCCR2TP53PKMHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230340328-A1 LIQUID-CRYSTALLINE MEDIUM MERCK PATENT GMBH (DE) 2023-10-26 US disclosed
US-20230272282-A1 LC MIXTURES WITH NEGATIVE DELTA EPSILONCONTAINING CC-4-V1 AND COB(S)-N-OM MERCK PATENT GMBH (DE) 2023-08-31 US disclosed
US-20230183571-A1 LIQUID-CRYSTAL MEDIUM COMPRISING POLYMERIZABLE COMPOUNDS MERCK PATENT GMBH (DE) 2023-06-15 US disclosed
US-11667845-B2 Liquid crystalline medium MERCK PATENT GMBH (DE) 2023-06-06 US disclosed
US-20180208848-A1 LIQUID CRYSTALLINE MEDIA HAVING HOMEOTROPIC ALIGNMENT MERCK PATENT GMBH (DE) 2018-07-26 US disclosed
EP-3235894-A2 LIQUID CRYSTALLINE MEDIUM Merck Patent GmbH (DE) 2017-10-25 EP disclosed
EP-2837671-B1 Liquid crystalline medium MERCK PATENT GMBH (DE) 2017-10-25 EP disclosed
EP-3228681-A1 LIQUID-CRYSTALLINE MEDIUM AND LIQUID-CRYSTAL DISPLAY COMPRISING THE SAME Merck Patent GmbH (DE) 2017-10-11 EP disclosed
WO-2017162716-A1 LIQUID-CRYSTALLINE MEDIUM MERCK PATENT GMBH (DE) 2017-09-28 WO disclosed
WO-2017162717-A1 LIQUID-CRYSTALLINE MEDIUM MERCK PATENT GMBH (DE) 2017-09-28 WO disclosed
EP-2248872-A2 Liquid crystalline medium Merck Patent GmbH (DE) 2010-11-10 EP disclosed
EP-2208774-A2 Liquid crystalline medium Merck Patent GmbH (DE) 2010-07-21 EP disclosed
US-7754103-B2 Liquid-crystalline medium MERCK PATENT GMBH (DE) 2010-07-13 US disclosed
EP-2199362-A2 Liquid crystalline medium Merck Patent GmbH (DE) 2010-06-23 EP disclosed
EP-2182046-A1 Liquid-crystalline medium and liquid crystal display Merck Patent GmbH (DE) 2010-05-05 EP disclosed
US-20090194738-A1 Liquid-crystalline medium MANABE ATSUTAKA 2009-08-06 US disclosed
EP-1658352-B1 LIQUID CRYSTALLINE MEDIUM MERCK PATENT GMBH (DE) 2008-04-02 EP disclosed
WO-2008025533-A1 LIQUID-CRYSTALLINE MEDIUM MERCK PATENT GMBH (DE) 2008-03-06 WO disclosed
EP-1832643-A1 Liquid crystalline medium and liquid-crystal display Merck Patent GmbH (DE) 2007-09-12 EP disclosed
US-7201951-B2 Liquid-crystalline medium MERCK PATENT GMBH (DE) 2007-04-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11667845-B2 Liquid crystalline medium NEFM, CCNI, MYT1 CTSK 1034/4885CCR2 1180/4885TP53 1756/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.